Jean-Michel Dogné on The Aspirin Dosing after Trump’s Announcement
Jean-Michel Dogné, Full Professor and Dean of the Faculty of Medicine at Namur University, shared on LinkedIn:
”Approximations and blatant errors…
From the great Trump
- The aspirin (ASA) does not “thin” or “liquefy” the blood!
Acetylsalicylic acid has no effect on blood viscosity.
Its mechanism of action is well known:
- inhibition of platelet aggregation,
- by irreversibly blocking platelet COX-1,
- leading to a decrease in thromboxane A₂ synthesis.
Talking about “thick blood” or “thin blood” is therefore a misleading simplification with no pathophysiological basis.
2. In cardiovascular (secondary) prevention, we are not talking about high doses!
The recommendations are very clear:
- Low-dose ASA, generally 75 to 100 mg per day.
Furthermore, in patients aged ≥ 70 with no history of cardiovascular disease, data show no net benefit from low-dose ASA and a significant increase in major bleeding!
In practice, the recommendations therefore advise against initiating ASA for primary prevention in these patients.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch